Get the latest news, insights, and market updates on ESPR (Esperion Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid as a first-line, evidence-based therapy for LDL-C lowering for patients on maximally tolerated statins in the 2025 American College of Cardiology (ACC) Scientific Statement on Management of Peripheral Artery Disease (PAD) Dec 19, 2025 - $ESPR
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results
Esperion Therapeutics has seen its fair value estimate nudged higher to about $6.50 per share from roughly $6.15, even as the discount rate holds steady near 6.96% and revenue growth expectations ease slightly to around 20.4% from approximately 20.7%. This recalibration reflects rising confidence in the company’s long term earnings power, tempered by cautious near term growth assumptions as analysts weigh the pace of commercial execution and market adoption. Read on to see how you can track... Dec 10, 2025 - $ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of 380,000 shares of common stock, all of which were granted to John Harlow, the Company’s newly appointed Chief Commercial Officer, and (ii) 435,536 restricted stock units (RSUs), 424,536 of which were awarded to Mr. Harlow, under Esperion’s 2017 Inducement Equity Incentive Plan. The Dec 9, 2025 - $ESPR
Why Analysts Are Rewriting Esperion’s Story After New Pipeline Results and Global Partnerships
Esperion Therapeutics has recently seen a slight increase in its fair value target, moving from $6.10 to $6.15 per share following adjustments to analysts’ expectations. This modest revision reflects both improved sentiment in recent coverage and evolving outlooks for the company’s potential revenue growth. As the narrative around Esperion continues to shift, staying informed will be key to understanding its future trajectory and opportunities. Analyst Price Targets don't always capture the... Nov 25, 2025 - $ESPR
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner in Japan for the development and commercialization of NEXLETOL® (bempedoic acid) tablets, received National Health Insurance Price Listing and launched NEXLETOL for t Nov 21, 2025 - $ESPR
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Espe Nov 19, 2025 - $ESPR
HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Health Canada has approved NILEMDO® (bempedoic acid) for use in Canada and has issued a Notice of Non-Compliance ("NON") for NEXLIZET® (bempedoic acid and ezetimibe). HLS in-licensed the exclusive rights to NILEMDO and NEXLIZET for the Canadian market from Esperion Therapeutics Inc. ("Esperion") Nov 18, 2025 - $ESPR
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026. “This approval marks a Nov 18, 2025 - $ESPR
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
– Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR Outcomes Reports Patients Who Took Bempedoic Acid Were 42% Less Likely to Experience Venous Thromboembolism Events Compared to Placebo – ANN ARBOR, Mich., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of two post hoc analyses from CLEAR Outcomes focused on Nov 10, 2025 - $ESPR
Tracking the Narrative for Esperion Therapeutics as Analyst Optimism Grows Amid Shifting Fundamentals
Esperion Therapeutics has seen its Fair Value Estimate tick up from $5.80 to $6.10, signaling a modest boost in the company’s assessed intrinsic worth. This adjustment comes as analysts show increasing optimism about the company’s growth prospects and execution in its target markets. Stay tuned to discover key ways you can monitor shifts in the company narrative and stay ahead of future updates. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find... Nov 9, 2025 - $ESPR
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple